


































































































































































































































































































































































































































Figure 1-1: Cellular metabolism 
Glycolysis generates a net gain of 2 ATP molecules per molecule of glucose, with complete 
oxidation of the pyruvate generated potentially yielding a further 36 molecules of ATP via 
OXPHOS. However, proliferating cells must also satisfy their need for biosynthetic 
intermediates by diverting intermediates away from ATP production. Abbreviations used: 
aldolase (ALDO), 1,3-Bisphosphoglyceric acid (GBP), dihydroxyacetone phosphate (DHAP), 
electron transport chain (ETC), enolase (ENO1), fructose 1,6 bisphosphate (FBP), fructose-6-
phosphate (F6P), glyceraldehyde-3-phosphate (GAP), glyceraldehyde-phosphate-
dehydrogenase (GAPDH), glutathione synthesis (GSH), glucose transporter 1 (GLUT1), 
glucose-6-phosphate (G6P), glucose phosphate isomerase (GPI), hexokinase (HK), lactate 
dehydrogenase (LDH), pyruvate dehydrogenase (PDH), phosphophenolpyruvate (PEP). 
phosphofructokinase (PFK), 2-phosphoglycerate (2-PG), 3-phosphoglyceric acid (3-PG), 
phosphoglycerate kinase (PGK), phosphoglycerate mutase (PGM), pyruvate kinase (PKM), 
















































Figure 1-2: The electron transport chain (ETC) 


























Figure 1-3: FDG-PET scanning 
18F-FDG scan showing high accumulation of the radiolabelled glucose-analogue in a 
colorectal tumour with liver metastases. Normal high accumulation in the bladder is also 
evident. Image from Jens Langer (11). It is important to stress that although tumourigenic cells 
undergo a relative shift towards glycolysis, in comparison to normal comparable cell types, the 
balance between OXPHOS and glycolysis used to generate ATP is cell type and context 

















































































(Figure legend on next page)
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Figure 1-4: Signaling pathways and cancer metabolism.
Figure adapted from Fundamental of Cancer Metabolism (31). A number of signal transduction 
pathways  converge on major metabolic pathways . In cancer dysregulation of these 
pathways shift the balance of energy generation pathways from OXPHOS towards glycolysis. 
Increased glycolytic flux generates increased levels of metabolites  which can fuel anabolic 
pathways. Directional arrows indicate where a metabolite is a substrate or 
intermediate/product of a given pathway. Abbreviations used; αKG (alpha-ketoglutarate); G6P 
(glucose-6-phosphate); 3-PG (3-phosphoglycerate); OAA (oxaloacetate). Therapeutic 









(Figure legend on next page) 
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Figure 1-5: Therapeutic approaches targeting the altered metabolic phenotype in 
cancer 
A multitude of different approaches have been investigated as a means of targeting the altered 
metabolic phenotype in cancer cells. Molecular targets of the named compounds are indicated 






































































































Figure 1-6: Structure of MCT1 
Predicted topology of MCT1. Homology model of MCT1 based upon the Glycerol-3-Phosphate 
Transporter from Escherichia coli (1pw4A) as previously described (67). The model was 



















L‐Lactate  3.5  0.74  6  28 
D‐Lactate  >60 ‐ ‐ 519 
Pyruvate  1  0.08  ‐  153 
α‐Ketobutyrate  0.2 ‐ ‐ 57 
Table 1: Substrate affinities of MCTs 
Km values (mM) for selected substrates of MCTs from studies expressing MCT1, 2 and 4 in 

































































































































































Figure 1-7: Chemical structures of non-selective MCT1 inhibitors  
Chemical structures recreated from Chemspider or using the following references; 7ACC 




























































































































































































































































































































































































































































































































































Table 2: Preclinical studies on the effects of non-specific or genetic MCT1 inhibition in cancer 
Abbreviations used: CHC (α-Cyano-4-hydroxycinnamic acid), 3BrPa (3-Bromopyruvic acid), 7ACC (7-aminocarboxycoumarin and derivatives) Where 
available the protein expression of MCT1 and 4 are indicated (+/-). Concentrations of intracellular and extracellular lactate were determined by 







Lactate Cell growth and 
viability 



























































































Lactate Cell growth and 
viability 




























































































Lactate Cell growth and 
viability 
































































Lactate Cell growth and 
viability 




































Table 3: Preclinical studies AZD3965 and structurally related MCT1 specific inhibitors  
Where available the protein expression of MCT1 and 4 are indicated (+/-). Concentrations of intracellular and extracellular lactate were determined by 



















































































































































Name Source Cell origin Patient details Subclassification c-MYC translocation Reference 
BL41 DSMZ  Tumour material  Primary diagnosis ‐ M (8)   N/A  t(8;14)  (141) 
Daudi DSMZ  Tumour material  Primary diagnosis ‐ M (16)  Endemic BL   t(8;14)  (141) 
CA46 DSMZ  Ascites fluid  M  Sporadic BL   t(8;14)  (141) 
Raji DSMZ  Tumour material  M (11)  Endemic BL  t(8;14)  (141) 
Ramos DSMZ  Tumour material  M (3)  Sporadic BL  t(8;14)  (141) 
BJAB DSMZ  Tumour material  F (5)  GCB/?  t(2;8)  (142) 
Farage ATCC  Lymph node biopsy  Primary diagnosis ‐ F (70)  GCB/BCR  None reported  (143, 144) 
OCILY18 DSMZ  Pleural fluid   Relapse ‐ M (56)  GCB/BCR  t(8;14;18)  (145) 
Pfeiffer ATCC  ‐  M (adult)  GCB/OXPHOS  t(8;14)  (146) 
Toledo ATCC  Peripheral blood leukocytes  Relapse ‐ F (adult)  GCB/OXPHOS  ?  (146) 
RIVA Prof. Alison 
Banham 
Peripheral blood leukocytes  Relapse ‐ F (57)  ABC/?  t(4;8)  (147) 
Table 4: Cell panel details 
Source of cell lines used in our study along information regarding their origin including patient sex, age and disease state (diagnosis or relapse) are 
indicated. Disease subtypes for Burkitt lymphoma (Sporadic/endemic) and Diffuse large B-cell lymphoma cell lines (COO: GCB/ABC, CCC: 

































































Protein Dilution Raised in Manufacture Product 
MCT1 
1:200  Goat  Santa Cruz  sc‐14916 
MCT4 
1:1000  Rabbit  Santa Cruz  sc‐50329 
CD147 
1:200  Mouse  Ancell  376‐820 
c-MYC 
1:1000  Rabbit  Abcam  ab32072 
PARP 
1:1000  Rabbit  Santa Cruz  sc‐7150 
β-actin 1:5000  Mouse  Abcam  ab‐8227 
Table 5: Primary antibodies used for western blotting  
All primary antibodies were prepared in 5% milk TBS-T and incubations were performed 












Figure 2-1: Western blotting procedure 




























































Figure 2-3: Principle of XTT assay 
The production of the formazan derivative, which has maximal absorbance at 450 nm, is 
catalyzed by mitochondrial reduction of XTT therefore; absorbance is proportional to the 






































































































































































































































































Figure 2-4: Seahorse bioanalyser technology 
To measure oxygen consumption and proton extrusion a transient microchamber is formed by 
the sensor moving towards the bottom of the well. Four injection ports are preloaded with 





















































































































Figure 2-5: Plasmid map of pSLIEW 
pSLIEW vector containing, enhanced green-fluorescent protein (EGFP), and firefly luciferase 
(fLuc) genes. Transduced GFP expression was used to sort transduced CA46 cells via FACS. 










































































Figure 3-1: MCT1 and MCT4 mRNA expression across disease subtypes 
A subset of 610 cell lines from CCLE (Affymetrix U133 +2) with gene expression data for MCT1 and MCT4 were categorized by disease type. Disease 
categories were sorted by the median of MCT4 expression. Individual hematological and solid cancers cell lines are displayed as  and  respectively. 
Abbreviations used: acute lymphocytic leukaemia (B/T-ALL), small-cell lung cancer (SCLC), diffuse large B-cell lymphoma (DLBCL), chronic myeloid 





Figure 3-2: Summary of MCT1 and MCT4 mRNA expression in the Cancer Cell Line 
Encyclopedia 
Scatterplot of normalized MCT1 and MCT4 expression in cancer cell lines from the Cancer 



























































































Figure 3-3: Characterization of MCT1 and MCT4 expression in BL and DLBCL cell lines 
Western blot showing the expression of MCT1 (54 kDa), MCT4 (49 kDa) and CD147 (42 kDa) 
in the panel of DLBLC and BL cell lines representative of two blots. Samples are whole cell 






Figure 3-4: Immunohistochemical staining of MCT1 and MCT4 in B-NHL cell lines 












Figure 3-5: Heat map distribution of MCT1 and 4 scoring in BL and DLBCL patient 
cohorts.  
BL and DLBCL patient samples were scored for intensity and extent of staining to produce a 
single expression score (H-score). Individual cases were sorted by MCT4 expression. 
Representative examples covering the range of MCT1/4 expression are marked (i-iii) with 
corresponding IHC images available in Figure 3-6. H-scores, Cell of Origin status and sample 













Figure 3-6:  Representative MCT1 and 4 staining in BL and DLBCL patient cohorts.  







Figure 3-7: Distribution of COO subtypes in DLBCL cohort 









Figure 3-8: COO sub-types do not exhibit specific expression profiles of MCT1/4  
Summary of immunohistochemical staining using H-scores for MCT1 and MCT4 in 120 DLBLC 




















study  also  included  analysis  of  129  DLBCL  patient  samples  and  showed  DLBCL  to  have 
comparatively low MCT1 expression as well as increased expression of MCT4 (GSE4475). This 
is  in contrast  to our  IHC data where MCT4 expression was undetectable  in  the majority of 
DLBCL patient  specimens. We also  found no association between MYC  rearrangement and 































































































Figure 4-1: AZD3965 increases intracellular lactate in human lymphoma cell lines 
Intracellular lactate was measured in cells following exposure to AZD3965 (1 µM) () or DMSO 
() vehicle for 24 hours as described in Section 2.5. Values shown have been normalised to 
protein content via BCA assay. The mean concentration of intracellular lactate following 
treatment with AZD3965 in MCT4 negative cell lines is indicated (▪▪▪). Data shown are the mean 
+ SEM of at least three independent experiments. P-values were calculated using an unpaired 

















Figure 4-2: AZD3965 triggers a rapid and sustained accumulation of lactate in CA46 
cells 
Intracellular lactate was measured in CA46 cells following exposure to AZD3965 (10-1000 nM) 
or DMSO vehicle at the indicated time-points (0.5-72 hours) as described in Section 2.5. Values 
shown have been normalised to protein content via BCA assay. Data shown are the mean + 


















Figure 4-3: AZD3965 has growth inhibitory activity in BL cell lines 
Exponentially growing Burkitt lymphoma cells were treated with increasing concentrations of 
AZD3965 for 72 hours before assessing metabolic activity in the cell population as a surrogate 
for cell number using an XTT assay, as described in Section 2.6. Individual dose-response 
curves are shown for BJAB (A), Daudi (B), BL41 (C), CA46 (D), Raji (E) and Ramos (F). 
Metabolic activity as a percentage of control was calculated relative to DMSO (0.01%) treated 
control cells after correcting for proliferation between seeding and dosing T0. Data shown are 





Figure 4-4: AZD3965 has growth inhibitory activity in DLBCL 
Exponentially growing Diffuse Large B-cell lymphoma cells were treated with increasing 
concentrations of AZD3965 for 72 hours before assessing metabolic activity in the cell 
population as a surrogate for cell number using an XTT assay, as described in Section 2.6. 
Individual dose-response curves are shown for Toledo (A), RIVA (B), Pfeiffer (C), OCILY18 (D) 
and Farage (E). Metabolic activity as a percentage of control was calculated relative to DMSO 
(0.01%) treated control cells after correcting for proliferation between seeding and dosing T0. 










Figure 4-5: Sensitivity of B-NHL cell lines to AZD3965 
GI50 values as determined by XTT assay after 72 hour treatment with AZD3965. GI50 was 
defined as the dose required to inhibit the metabolic reduction of XTT by 50%. Data shown are 























Figure 4-6: AZD3965 is cytostatic in DLBCL and BL which lack MCT4 
Exponentially growing BL or DLBCL cells were treated with AZD3965 (100 nM) or doxorubicin 
(1 µM) for 72 hours before performing cell counts using a hemocytometer. Cell number (A) 
data are shown as a percentage of each corresponding cell line matched DMSO (0.01%) 
treated control population. Cell viability (B) as assessed by trypan blue exclusion are shown 

























Figure 4-7: Extended incubation with AZD3965 does not induce substantial cell death 
CA46 or Raji cells were treated with AZD3965 (100 nM) for 120 hours before performing cell 
counts using a heamocytometer. Cell number () and cell viability () data are shown as a 
percentage of the respective cell line matched, DMSO (0.01%) treated control population. Cell 
viability was assessed by trypan blue exclusion. Data shown are the mean ± SEM of three 



















Figure 4-8: Acute oral treatment with AZD3965 induced lactate accumulation in BL 
tumour xenografts 
Concentrations of tumour lactate were measured in subcutaneous BL xenografts taken 2 hours 
following oral administration with AZD3965 (100 mg.kg-1) or vehicle as indicated. Intracellular 
lactate concentrations were determined ex vivo by biochemical assay and normalised to 
protein as described in Section 2.5. P-values were calculated using an unpaired Student’s t-











































Figure 4-9: Efficacy of AZD3965 in an intravenous in vivo model of Burkitt lymphoma 
NSG mice were transplanted with luciferase-expressing CA46 cells and treated with AZD3965 
(100 mg.kg-1, BID) or vehicle control for 24 days, following successful engraftment (6 days). 
Scans were performed at 3,10,17 and 24 days of treatment as described in Section 2.11. Data 
points show the mean + SEM of n=8 vehicle treated n=7 AZD3965 treated animals on a linear 
scale. 












Figure 4-10: AZD3965 attenuates CA46 xenografts growth  
NSG mice were transplanted with luciferase-expressing CA46 cells and treated with AZD3965 
(100 mg.kg-1, BID) or vehicle control for 24 days, following successful engraftment (6 days). A, 
the individual responses of mice treated with vehicle or AZD3965 pre-treatment (day 0) and 
post-treatment (day 24). Comparisons of paired samples pre-treatment and post-treatment. 
Significance was assessed by paired two-tailed t-test. Comparison between treatment groups 
before and after treatment. Significance was assessed by unpaired two-tailed t-test (*P ≤ 0.05, 
**P ≤ 0.01 ***P ≤ 0.001). B, Scans were performed at 3,10,17 and 24 days of treatment as 
described in Section 2.11. Data points show the mean + SEM of n=8 vehicle treated n=7 








































Figure 4-11: Bioluminescence of CA46 xenografts following treatment with AZD3965 
Representative images of an individual mouse from AZD3965 and vehicle treated groups 
showing the expansion of luciferase-expressing transduced CA46 cells over time. Mice prior 
to treatment period (day 6) and during treatment are shown on different radiance scales 









Figure 4-12: Time course of CA46 engraftment in mice receiving AZD3965 
Representative images of an individual AZD3965-treated mouse showing the expansion of 
luciferase-expressing transduced CA46 cells over time on a consistent radiance scale 
(p/sec/cm2/sr). 
 .
Figure 4-13: AZD3965 reduces spleen and bone marrow engraftment of BL 
Spleen weights were recorded post treatment, a representative image of an enlarged vehicle 
treated spleen is shown alongside a spleen taken from an AZD3965 treated mouse. Also 
shown are the individual spleen weights for each mouse (A). Reference non-engrafted spleen 
weights of NSG mice are typically 0.025-0.03 g (data not shown) (159). Representative 
immunohistochemical analysis of human CD20 in spleen sections and bone marrow sections 









































































































































































Figure 5-1: In vitro metabolic changes following acute treatment with AZD3965 
Metabolic changes following 2 hour treatment with AZD3965 in BL (CA46, Daudi, Raji), DLBCL (Farage and OCILY18) and neuroblastoma (IMR-32, 
SH-SY5Y) cells. Significant (P-value ≤ 0.05) and substantial (+/- 0.5 Log2 fold change) alterations in intracellular metabolite concentrations relative to 
time-matched DMSO controls, are labelled by metabolite name. Abbreviations used: aKET B (α-ketoglutarate or oxoglutarate), AMP (Adenosine 
monophosphate), CMP (Cytidine monophosphate), dCMP (2'Deoxycytidine monophosphate), dUMP (2'-Deoxyuridine 5'- triphosphate), dUTP (2'-
Deoxyuridine 5'- triphosphate), Fructose-1-P (Fructose-1-phosphate), Fructose-6-P (Fructose-6-phosphate), FBP (Fructose bisphosphate), Glucose-1-
P (Glucose-1-phosphate), Glucose-6-P (Glucose-6-phosphate), glutathione red (Reduced glutathione),GAP (Glyceraldehyde-3-phosphate), GBP 
(Glycerate bisphosphate), IMP (Inositol monophosphate), Mannose-6-P (Mannose-6-phosphate), NAD (Nicotinamide adenine dinucleotide) PG 
(Phosphogluconate), Pserine (Phosphoserine), Ribose-5-P (Ribose-5-phosphate), Ribulose-5-P (Ribulose-5-phosphate), TMP (Thymidine 









Figure 5-2: Summary of the AZD3965-induced changes in glycolytic and TCA cycle 
intermediates in B-NHL 
Concentrations of intracellular metabolites significantly altered (P-value ≤ 0.05) relative to time-
matched DMSO control, which are substantially altered (+/- 0.5 Log2 fold change) are labelled 
by metabolite name. A number of metabolites were not detectable in both vehicle-treated and 
AZD3965-treated samples consequently log2 FC values could not be derived. Metabolites 
exclusively detected in AZD3965 treated cells were isocitrate (Daudi) and GBP (Farage). 
Abbreviations used: αKG (α-ketoglutarate or oxoglutarate), F6P (Fructose-6-phosphate), FBP 
(Fructose bisphosphate), G1P (Glucose-1-phosphate), G6P (Glucose-6-phosphate), GAP 
















Figure 5-3: TCA cycle pathway analysis in CA46 cells 
Log2 fold changes in metabolites are plotted onto the KEGG pathway database (Hsa00020) 
using the R/Bioconductor package Pathview (188). Significantly (P < 0.05) altered metabolites 
are colour coded by log2 fold change. In this example, data are taken from CA46 cells after 2 
hour treatment with AZD3965 (100 nM). Metabolites not significantly altered by drug treatment 
(black nodes), those which failed LC-MS quality control (patterned nodes) or metabolites which 



























Figure 5-4: Metabolic alterations in Raji xenografts triggered by acute treatment of 
AZD3965 
Changes in intracellular metabolites 2 hours after treatment with AZD3965 (100mg.kg-1) 
in Raji xenografts. 130 metabolites were analysed using GC-MS by S. Solanki (Imperial 
College London). Concentrations of metabolites that were significantly altered (P value ≤ 
0.05) relative to time-matched vehicle control, which are substantially altered (+/- 0.5 Log2 
fold change) are shown. Shapes are coloured according to log2 fold change and sized by 






Figure 5-5: Metabolic alterations in CA46 xenografts triggered by acute treatment of 
AZD3965 
A, Log2FC changes following 2 hour treatment with AZD3965 (100mg.kg-1) in CA46 
xenografts relative to time-matched vehicle controls. Changes in intracellular metabolites. 
Samples were analysed using GC-MS by A. Sikka (Imperial College London). B, shows 
the individual metabolite intensity values (relative concentration) that were significantly 





















































































































Figure 5-6: XTT assay of CA46 and CA46-R cells in response to AZD3965 
Exponentially growing CA46 or CA46-R cells were treated with increasing concentrations of 
AZD3965 for 72 hours before assessing metabolic activity in the cell population as a surrogate 
for cell number using an XTT assay, as described in Section 2.6. Metabolic activity as a 
percentage of control was calculated relative to DMSO (0.01%) treated control cells after 
correcting for proliferation between seeding and dosing T0. Data shown are the mean ± SEM 

















Figure 5-7: Sensitivity to AZD3965 and CA46 and CA46-R cells 
Exponentially growing CA46 or CA46-R cells were treated with AZD3965 (100 nM) or 
doxorubicin (1 µM) for 72 hours before performing cell counts using a hemocytometer. Cell 
number data are shown as a percentage of a, cell line matched, DMSO (0.01%) treated control 
population. The significance of any changes relative to DMSO control was assessed using 
unpaired Student’s t-tests (*P ≤ 0.05, **P ≤ 0.01 ***P ≤ 0.001). Data shown are the mean ± 
SEM of three independent experiments. 
119 
Figure 5-8: Cell viability in CA46 and CA46-R cells following AZD3965 or doxorubicin 
treatment  
Exponentially growing CA46 or CA46-R cells were treated with AZD3965 (100 nM) or 
doxorubicin (1 µM) for 72 hours before assessing cell viability by trypan blue exclusion. Data 
are shown as a percentage of a cell line matched DMSO (0.01%) treated control population. 

















Figure 5-9: Doubling times of CA46 & CA46-R cells 
Exponentially growing CA46 and CA46-R cells were seeded in their standard drug-free media 
and cell counts performed every 24 hours to determine proliferative rate. Doubling times were 
determined using an exponential growth equation in Graphpad. Data shown are the mean ± 





















Figure 5-10: Intracellular lactate accumulation in CA46 & CA46-R following AZD3965 
treatment 
Intracellular lactate was measured in cells following exposure to () AZD3965 (1 µM) or () 
DMSO vehicle for 24 hours as described in Section 2.5. Values shown have been normalised 
to protein content via BCA assay. Data shown are the mean + SEM of at least 3 independent 






Figure 5-11: Expression of MCT1, MCT4 and CD147 in CA46 CA46-R cells  
Protein expression of MCT1 (54 kDa) and MCT4 (49 kDa) and chaperone CD147 shown in 
comparison to parental CA46 cells. BJAB are included as an MCT4 expressing control. One 












Figure 5-12: Extracellular metabolite analysis in CA46 and CA46-R cells 
Extracellular metabolite concentrations were measured following exposure to AZD3965 (100 
nM) or DMSO vehicle for 24 hours, as described in (Section 2.7.3. ). Values shown have been 
normalised to cell number. Data shown are the mean + SEM of 4 technical replicates. P-values 


















Figure 5-13: Oxygen consumption rate (OCR) in CA46 and CA46-R cells 
Oxygen consumption rate in CA46 () and CA46-R () was normalised to protein 
concentration via BCA assay following phenotypic analysis using the SeaHorse XF24. 







































Figure 5-14: Extracellular acidification rate (ECAR) in CA46 and CA46-R cells  
































































Figure 5-15: Summary of in vitro metabolic alterations following MCT1 inhibition with 
AZD3965.
Intracellular metabolites which were significantly by 2 hour exposure to AZD3965 (100 nM) 











































































Novel agent (Target) Combination Phase Population NCT identifier 
AT13387 (Hsp90)  None  2  Relapsed/refractory patients  NCT02572453 
AZD2014 (mTOR)  +/‐ Rituximab  2  Relapsed/refractory patients  NCT02752204 
Bortezomib (Proteosome inhibitor)  R‐CHOP  2  Untreated patients  NCT02542111 
Chidamide (HDAC)  VDDT  2  Relapsed/refractory patients  NCT02733380 
CUDC‐907 (HDAC)  +/‐ Rituximab  2  Relapsed/refractory patients  NCT02674750 
Entospletinib (SYK)  None  2  Relapsed/refractory patients  NCT01799889 
Ibrutinib (BTK)  R‐GEMOX‐Dexa  2  Relapsed/refractory patients  NCT02692248 
Ibrutinib (BTK)  R‐CHOP  2  Untreated EBV+ patients  NCT02670616 
INCB18424 (JAK)  None  2  Relapsed/refractory patients  NCT01431209 
Metformin (Complex I)  R‐CHOP  2  Untreated patients  NCT02531308 
Metformin (Complex I)  DA‐EPOCH‐R  2  Untreated patients  NCT02815397 
Selinexor (CRM1)  None  2  Relapsed/refractory patients  NCT02227251 
Sirolimus (mTOR)  Methotrexate  2  Relapsed/refractory patients  NCT01162551 
Tazemetostat (EZH2)  Various   2 ‐ NCT02875548 
TGR‐1202 (PI3Kδ), Ibrutinib (BTK)  TGR‐1202 + Ibrutinib 2  Relapsed/refractory patients  NCT02874404 
Lenalidomide  +/‐ R‐CHOP  3  Untreated patients  NCT02285062 
Lenalidomide  +/‐ R‐miniCHOP  3  Treated rituximab naïve patients  NCT02128061 
TGR‐1202 (PI3Kδ)  +/‐ Ublituximab  2|3  Relapsed/refractory patients  NCT02793583 
Table 8: Ongoing Phase II and III trials with novel targeted compounds in BL and DLBCL 
(Legend on next page)
133 
The advanced search function of Clinicaltrials.gov was used to search for ongoing 
interventional phase 2 or 3 clinical trials for the treatment of ‘Diffuse large B-cell lymphoma’ or 
‘Burkitt lymphoma’. Trials investigating novel biologicals were not included. Where novel 
agents are being tested alongside existing or novel combination therapies this is stated. 
Combination acronyms; R-CHOP (Rituximab), R-GEMOX (Rituximab, gemcitabine, oxaliplatin, 
dexamethasone), DA-EPOCH-R (Dose-adjusted rituximab, etoposide, prednisone, vincristine, 
doxorubicin, cyclophosphamide.), VDDT (Vinorelbine，Liposomal doxorubicin or mitoxantrone 





































































Table 9: GI50 values in CA46 and Raji
GI50 values calculated based on the mean metabolic activity measured by XTT assay across 












































































































Figure 6-1: Inhibitor sensitivity in CA46 and Raji
Exponentially growing CA46 and Raji cells were treated with increasing concentrations of the 
indicated inhibitors for 72 hours. The molecular targets the named inhibitors are indicated in 
individual graph titles. Metabolic activity as a percentage of control was calculated relative to 
DMSO (0.01%) treated control cells after correcting for proliferation between seeding and 
dosing T0. Data shown are the mean ± SEM of N experiments as indicated in Table 9, single 
























































ܥܫ ൌ ሺܦ௔௟௢௡௘ሻଵሺܦ௖௢௠௕௜௡௔௧௜௢௡ሻଵ ൅
ሺܦ௔௟௢௡௘ሻଶ
ሺܦ௖௢௠௕௜௡௔௧௜௢௡ሻଶ 
Combination index: Numerators are the dose associated with a given inhibitory effect for 
compound 1 and 2. Denominators are the dose of each compound necessary to illicit the same 
inhibitory response when used in combination. CI<1, C1=1, and CI>1 indicate synergism, 









Figure 6-2: Combination of mTOR inhibitor AZD8055 and AZD3965 in CA46 and Raji 
cells 
CA46 and Raji cells were treated with equipotent doses of AZD3965 and AZD8055 for 72 
hours. Metabolic activity as a percentage of control was calculated relative to DMSO (0.01%) 
treated control cells after correcting for proliferation between seeding and dosing T0. Data show 







Figure 6-3: Combination with BCL2 inhibitor ABT-199 in OCILY18 
OCILY18 cells were treated with equipotent doses of AZD3965 and ABT-199 for 72 hours. 
Metabolic activity as a percentage of control was calculated relative to DMSO (0.01%) treated 
control cells after correcting for proliferation between seeding and dosing T0. Data show the 
























Figure 6-4: Combination of AZD3965 with a Complex I inhibitors reduces cell viability 
(A), exponentially growing Raji cells were treated with rotenone (5 nM), AZD3965 (100 nM), 
combination or a DMSO vehicle control for 72 hours before assessing cell viability by trypan 
blue exclusion. Data shown are the mean + SD of two independent experiments. (B) 
exponentially growing Raji cells were treated with metformin (1 mM), AZD3965 (100 nM), 
combination or a DMSO vehicle control for 72 hours before assessing cell viability every 24 


















































Figure 6-5: AZD3965 and BAY 87-2243 induces cell death in Raji
Exponentially growing Raji cells were treated after 24 hours with AZD3965 (5 nM) or BAY 87-
2243 (100 nM) or both in combination a further 72 hours before performing cell counts using a 
hemocytometer. Cell number data are shown as a percentage of a cell line matched DMSO 
(0.01%) treated control population. Cell viability as assessed by trypan blue exclusion are 




















 Figure 6-6: BAY 87-2243 reduces OCR and spare respiratory capacity 
Oxygen consumption rate (OCR) was measured in CA46 cells. BAY 87-2243 (100 nM) or 
vehicle was added after establishment of a baseline measure of OCR. OCR was normalised 
to protein concentration via BCA assay following phenotypic analysis using the SeaHorse 
XF24. Abbreviations used: FCCP (Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone)); 
































Figure 6-7: Increased sensitivity in CA46-R to BAY 87-2243 
Exponentially growing CA46 or CA46-R cells were treated with increasing concentrations of 
BAY 87-2243 for 72 hours before assessing metabolic activity in the cell population as a 
surrogate for cell number using an XTT assay, as described in Section 2.6. Metabolic activity 
as a percentage of control was calculated relative to DMSO (0.01%) treated control cells after 
correcting for proliferation between seeding and dosing T0. Data shown are the mean ± SEM 




































Figure 6-8: AZD3965 and BAY 87-2243 induces BL cell death 
Exponentially growing CA46 or CA46-R cells were treated after 24h with AZD3965 (10 nM) or 
BAY 87-2243 (10 nM) or both in combination a further 72 hours before performing cell counts 
using a hemocytometer. Cell number data are shown as a percentage of a cell line matched 
DMSO (0.01%) treated control population. Cell viability as assessed by trypan blue exclusion 









Figure 6-9: Positive and negative controls for Cell-ROX assays 
Cellular debris was excluded using the FSC-SSC plot expressed in arbitrary units. Positive 
controls were prepared in CA46 cells using menadione (100 nM) for 1 hour prior to analysis. 
Negative controls were prepared using N-acetyl cysteine (NAC) pre-treatment for 1 hour before 
menadione or vehicle treatment. Intracellular ROS was measured flow cytometry for CellROX 








Figure 6-10: AZD3965 and BAY 87-2243 both increase intracellular ROS 
CA46 cells were treated with vehicle, AZD3965 (100 nM), BAY 87-2243 (100 nM), or 
combination for 48 hours and analysed by flow cytometry for CellROX fluorescence (FL-1). 




















Figure 6-11: AZD3965 in combination with BAY 87-2243 in well tolerated in non-tumour 
bearing mice 
Weights recorded at the indicated intervals were compared to individual mouse weights at the 
beginning of treatment to give a % change. Data points show the mean + SEM % change taken 






Figure 6-12: Study format for the assessment of AZD3965 and BAY 87-2243 in vivo 
Twelve days post implantation mice were assigned to one of four treatment groups and treated 
as indicated. Following a drug-free wash-out period tumour burden was measured at the 














Figure 6-13: Efficacy of the combination of AZD3965 and BAY 87-2243 in vivo 
NSG mice were intravenously inoculated with luciferase-expressing CA46 cells and allowed to 
engraft for 12 days prior to treatment with AZD3965 (100 mg.kg-1, BID), BAY 87-2243 (9 mg.kg-
1, OD) or the combination of AZD3965 and BAY 87-2243, for 14-days. Control and 
monotherapy-treated mice received the relevant vehicle controls. Mice were re-imaged at 
intervals from 72 hours following treatment. A, bioluminescent signals for mice within each 
group. The individual responses of mice treated with vehicle or AZD3965 pre-treatment (day 
12) and post-treatment (day 29). Comparisons of paired samples pre-treatment and post-




















Figure 6-14: Visualisation of the efficacy of the combination of AZD3965 and BAY 87-
2243 in vivo  
NSG mice were intravenously inoculated with luciferase-expressing CA46 cells and allowed to 
engraft for 12 days prior to treatment with AZD3965 (100 mg.kg-1, BID), BAY 87-2243 (9 mg.kg-
1, OD) or the combination of AZD3965 and BAY 87-2243, for 14-days. Representative images 
taken of a mouse from each treatment group are shown pre-treatment (day 12) and post-
treatment (day 29). Images are displayed on a single radiance scale, due to the wide range in 
signal intensities pre and post treatment which necessitates post-treatment control images are 







Figure 6-15: Visualisation of the progression of CA46 post-treatment in vivo. 
NSG mice were intravenously inoculated with luciferase-expressing CA46 cells and allowed to 
engraft for 12 days prior to treatment with AZD3965 (100 mg.kg-1, BID), BAY 87-2243 (9 mg.kg-
1, OD) or the combination of AZD3965 and BAY 87-2243, for 14-days. Representative images 
taken of a mouse from each treatment group are shown pre-treatment (day 12) and post-









Figure 6-16: Progression of CA46 post-treatment in vivo. 
NSG mice were intravenously inoculated with luciferase-expressing CA46 cells and allowed to 
engraft for 12 days prior to treatment with AZD3965 (100 mg.kg-1, BID), BAY 87-2243 (9 mg.kg-
1, OD) or the combination of AZD3965 and BAY 87-2243, for 14-days. Control and 
monotherapy-treated mice received the relevant vehicle controls. Mice were re-imaged at 
intervals from 72 hours following treatment. Scans were performed at 12, 29, 34, 41 and 48 







Figure 6-17: The oral dosing regimen of AZD3965 and BAY 87-2243 is well tolerated 
Weights recorded at the indicated intervals were compared to individual mouse weights at the 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































16/611  BL  n/a  Y  300  0 
16/768  BL  n/a  Y  300  0 
16/817  BL  n/a  N  300  0 
16/391  BL  n/a  Y  300  0 
16/818  BL  n/a  Y  300  0 
16/827  BL  n/a  Y  300  0 
16/558  BL  n/a  N  300  0 
16/841  BL  n/a  Y  300  0 
16/511  BL  n/a  Y  300  2 
16/321  BL  n/a  n.d  300  10 
PR29428/07  DLBCL  ABC  N  170  0 
PR32298/07  DLBCL  GCB  N  240  0 
PR42830/07  DLBCL  ABC  N  300  0 
PR3089/08  DLBCL  ABC  N  220  0 
PR9008/08  DLBCL  ABC  N  290  0 
PR13580/08  DLBCL  ABC  Y  100  0 
PR23480/08  DLBCL  GCB  n.d  300  0 
PR29746/08  DLBCL  GCB  N  20  0 
PR43029/09  DLBCL  GCB  n.d  70  0 
PR32817/11  DLBCL  GCB  n.d  200  0 
PR29109/11  DLBCL  GCB  n.d  20  0 
PR23302/11  DLBCL  GCB  n.d  20  0 
PR20297/04  DLBCL  GCB  Y  240  0 
PR28506/05  DLBCL  GCB  N  130  0 
PR40579/05  DLBCL  ABC  N  110  0 
PR14004/04  DLBCL  GCB  N  100  0 
PR25724/06  DLBCL  ABC  N  170  0 
PR28320/06  DLBCL  ABC  N  170  0 
PR40465/06  DLBCL  ABC  N  100  0 
PR16937/07  DLBCL  GCB  N  140  0 
PR19169/07  DLBCL  GCB  N  280  0 









PR29951/07  DLBCL  GCB  Y  300  0 
PR5697/08  DLBCL  ABC  N  50  0 
PR15963/08  DLBCL  ABC  N  150  0 
PR25086/08  DLBCL  GCB  Y  300  0 
PR24199/08  DLBCL  GCB  N  270  0 
PR40812/08  DLBCL  GCB  Y  290  0 
PR43968/08  DLBCL  GCB  N  280  0 
PR2676/09  DLBCL  ABC  Y  120  0 
PR19148/09  DLBCL  ABC  n.d  290  0 
PR29270/09  DLBCL  GCB  Y  300  0 
PR29864/09  DLBCL  GCB  n.d  200  0 
PR25618/07  DLBCL  GCB  N  150  0 
PR6621/07  DLBCL  ABC  N  260  0 
PR2486/07  DLBCL  GCB  N  240  0 
PR36972/06  DLBCL  GCB  n.d  120  0 
PR32034/06  DLBCL  GCB  N  260  0 
PR23084/06  DLBCL  GCB  Y  280  0 
PR36304/03  DLBCL  GCB  N  30  0 
PR3902/04  DLBCL  ABC  N  170  0 
PR20367/08  DLBCL  GCB  n.d  300  0 
PR40146/03  DLBCL  GCB  n.d  280  0 
05/13561  DLBCL  ABC  Y  200  0 
1210827  DLBCL  ABC  N  280  0 
PR20761/05  DLBCL  GCB  N  290  0 
PR9693/07  DLBCL  GCB  N  180  0 
07H12708  DLBCL  GCB  Y  20  0 
P06/8605  DLBCL  ABC  N  300  0 
P07/14124  DLBCL  GCB  N  90  0 
P05/7489  DLBCL  GCB  N  210  0 
PR3219/06  DLBCL  GCB  N  300  0 
07H13399  DLBCL  GCB  n.d  70  0 
PR34622/09  DLBCL  ABC  N  90  0 
PR28424/07  DLBCL  ABC  N  20  0 
PR13924/07  DLBCL  GCB  Y  290  0 
PR37065/04  DLBCL  GCB  n.d  300  0 









PR26840/05  DLBCL  GCB  N  260  0 
PR23944/07  DLBCL  ABC  n.d  200  0 
PR1825/05  DLBCL  GCB  N  300  0 
PR41673/08  DLBCL  GCB  n.d  50  0 
08/02315  DLBCL  GCB  n.d  250  0 
04/4472 A5  DLBCL  GCB  N  280  0 
PR22517/06  DLBCL  GCB  n.d  40  0 
07H8249  DLBCL  ABC  N  80  0 
PR21189/06  DLBCL  GCB  n.d  50  0 
PR21012/07  DLBCL  ABC  n.d  280  0 
PR16109/04  DLBCL  GCB  n.d  230  0 
PR15362/08  DLBCL  GCB  n.d  250  0 
PR40855/06  DLBCL  GCB  N  300  0 
08/10760  DLBCL  ABC  N  10  0 
PR35436/05  DLBCL  GCB  n.d  260  0 
04/12376  DLBCL  GCB  N  300  0 
PR11576/15  DLBCL  ABC  N  300  0 
PR30622/14  DLBCL  ABC  n.d  250  0 
PR41399/13  DLBCL  ABC  n.d  130  0 
PR31383/13  DLBCL  GCB  N  300  0 
PR48484/15  DLBCL  GCB  N  240  0 
PR53103/13  DLBCL  GCB  n.d  160  0 
PR31909/14  DLBCL  GCB  Y  300  0 
PR4823/15  DLBCL  GCB  n.d  110  0 
PR41003/14  DLBCL  GCB  N  260  0 
PR09549/16  DLBCL  GCB  N  300  0 
PR18025/15  DLBCL  GCB  n.d  300  0 
PR47674/14  DLBCL  GCB  N  300  0 
PR47462/14  DLBCL  GCB  N  300  0 
PR33799/13  DLBCL  GCB  Y  130  0 
PR23721/14  DLBCL  GCB  Y  250  0 
PR16506/06  DLBCL  GCB  N  110  2 
PR14330/08  DLBCL  GCB  N  300  2 
713474  DLBCL  ABC  N  230  2 
PR4666/05  DLBCL  ABC  N  50  2 









PR06607/15  DLBCL  GCB  N  30  2 
PR15175/11  DLBCL  ABC  n.d  280  4 
PR10234/08  DLBCL  ABC  N  270  5 
PR1592/06  DLBCL  GCB  N  100  5 
PR36943/09  DLBCL  GCB  N  200  10 
PR43202/11  DLBCL  GCB  n.d  300  10 
PR17512/07  DLBCL  GCB  N  250  10 
PR23739/14  DLBCL  ABC  n.d  220  15 
PR14786/11  DLBCL  GCB  n.d  100  20 
PR24260/05  DLBCL  GCB  N  180  20 
PR33076/04  DLBCL  ABC  n.d  270  20 
PR14748/14  DLBCL  ABC  n.d  300  20 
PR32466/08  DLBCL  GCB  N  220  30 
PR20422/06  DLBCL  GCB  N  170  40 
PR21162/08  DLBCL  GCB  n.d  120  40 
PR3257/06  DLBCL  GCB  N  90  60 
PR35058/15  DLBCL  ABC  N  60  80 
PR06734/15  DLBCL  GCB  N  200  90 
08H06103  DLBCL  GCB  N  270  100 
PR4068/06  DLBCL  GCB  N  220  110 
PR26201/05  DLBCL  GCB  N  230  120 
P06/16727‐4  DLBCL  GCB  n.d  280  150 
PR10496/05  DLBCL  GCB  N  140  160 
PR32255/11  DLBCL  ABC  n.d  240  170 
PR1266/08  DLBCL  ABC  n.d  300  190 
PR15144/06  DLBCL  GCB  N  260  200 
PR41023/06  DLBCL  GCB  n.d  300  250 
Table 10: BL/DLBCL samples stained for MCT1 and MCT4 expression by IHC  
Individual cases were sorted by disease type (BL or DLBCL) and then by MCT4 expression. 
Cell of Origin status is indicated where defined (ABC/GCB), not determined (n.d) or not 
applicable (n/a). Presence of MYC translocation as identified by FISH is indicated as confirmed 
(Y), no evidence (N) or not defined (?). BL and DLBCL patient samples were scored for 










Akata  BL  MUT     n/a        1915267 
AKUA  BL  MUT     non‐functional        8402660 
AS283A  BL  MUT     n/a        2052620 
BL113  BL  MUT     non‐functional        2052620 
BL‐37  BL  MUT     non‐functional        2052620 
BL‐41  BL  MUT     non‐functional  9.84  4.47  15188009 
BL‐49  BL  MUT     non‐functional        2052620 
BL‐60  BL  MUT     non‐functional        2052620 
BL‐70  BL  MUT     non‐functional  8.76  4.51  15188009 
BL‐99  BL  MUT     n/a        2052620 
BRG‐A  BL  MUT     n/a        9399658 
BRG‐M  BL  MUT     non‐functional        9399658 
CA46  BL  MUT     non‐functional  9.19  4.87  8402660 
CW678  BL  MUT     non‐functional  8.63  4.89  2052620 
Daudi  BL  MUT     non‐functional  8.63  4.89  15188009 
DG‐75  BL  MUT     functional        9525742 
EB‐1  BL  MUT     non‐functional  9.17  4.68  15188009 
EB2  BL  MUT     non‐functional  8.93  4.85  15188009 
EB3  BL  MUT     n/a        2052620 
GA‐10  BL  MUT     non‐functional   9.30  4.85  11482875 
JD 38  BL  MUT     non‐functional        2052620 
Jijoye  BL  MUT     non‐functional        1915267 
KK125  BL  MUT     non‐functional        2052620 
Louckes  BL  MUT     non‐functional        1915267 
MC116  BL  MUT     non‐functional  9.19  5.32  2052620 
Namalwa  BL  MUT     non‐functional  9.54  5.56  2052620 
P3HR‐1  BL  MUT     non‐functional        2052620 
PP984  BL  MUT     non‐functional        2052620 
Raji  BL  MUT     non‐functional  9.52  5.03  1915267 
Ramos  BL  MUT     non‐functional        2052620 
SG568  BL  MUT     n.d        8402660 
ST486  BL  MUT     non‐functional  8.71  4.72  15188009 
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TE‐161‐T  BL  WT       n/a        15188009 
BJAB  DLBCL  MUT     non‐functional        1915267 
CTB‐1  DLBCL  WT      n/a         15188009 
DB  DLBCL  MUT     non‐functional  8.99  4.79  15188009 
DOHH‐2  DLBCL  WT       n/a  8.41  4.71  15188009 
Farage  DLBCL  MUT     n.d        2748725 
HBL‐1  DLBCL  MUT     non‐functional        8412324 
HT  DLBCL  MUT     non‐functional  9.50  6.28  15188009 
KARPAS‐422  DLBCL  MUT     n/a  9.23  4.61  15188009 
OCILY1  DLBCL  MUT     non‐functional        8274734 
OCILY17  DLBCL  MUT     non‐functional        8274734 
OCILY2  DLBCL  MUT     non‐functional        8274734 
OCILY7  DLBCL  MUT     non‐functional        8274734 
Ly‐8C3  DLBCL  MUT     non‐functional        8274734 
NU‐DHL‐1  DLBCL  MUT     non‐functional  10.11  5.07  22460905 
OCILY10  DLBCL  WT       n/a  9.21  5.12  19021061 
OCILY18  DLBCL  MUT      n.d        8574164 
OCILY3  DLBCL  WT       n/a  8.80  4.66  19021061 
OCILY4  DLBCL  MUT     non‐functional        8574164 
Pfeiffer  DLBCL  MUT      n.d        21394100 
RIVA  DLBCL  MUT     non‐functional  10.01  6.49  22460905 
SU‐DHL‐1  DLBCL  MUT     non‐functional  10.20  4.98  15188009 
SU‐DHL‐10  DLBCL  MUT     n/a  9.61  5.39  22460905 
SU‐DHL‐4  DLBCL  MUT     non‐functional  9.34  5.03  22460905 
SU‐DHL‐6  DLBCL  MUT     n/a  9.46  4.73  22460905 
SU‐DHL‐8  DLBCL  MUT     non‐functional  9.16  5.18  22460905 
Toledo  DLBCL  MUT     n/a  8.63  4.95  22460905 
TUR  DLBCL  MUT     n/a        15188009 
WSU‐DLCL2  DLBCL  MUT     non‐functional  9.60  4.90  22460905 
Table 11: Summary of TP53 status and MCT1/MCT4 gene expression in BL and DLBCL 
Relative expression of MCT1 and MCT4 mRNA (RMA-normalised) from CCLE for BL and 








































































































































Table 12: Array of metabolites detectable by LC-MS  
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Appendix E: AZD3965 induced metabolic changes in vitro 
Cell line  Metabolites  Log2 FC  P‐value 
CA46  α‐ketoglutarate  0.72  0.02364856 
CA46  Aspartic acid  ‐0.55  0.01123613 
CA46  Benzoic acid  0.76  0.03698818 
CA46  Cis‐aconitic acid  1.92  0.00186559 
CA46  Citrate  2.50  0.03527132 
CA46  Fructose bisphosphate  ‐3.16  0.03645213 
CA46  Fructose‐1‐phosphate  ‐1.46  0.01015639 
CA46  Fructose‐6‐phosphate  1.38  0.03452481 
CA46  Fumarate  1.17  0.00030609 
CA46  Glucose‐6‐phosphate  1.37  0.02149326 
CA46  Hydroxy‐glutaric acid  0.61  0.00423076 
CA46  Inosine monophosphate  0.88  0.01666035 
CA46  Isocitrate  2.21  0.0233072 
CA46  Lactate  0.95  8.63E‐05 
CA46  Malate  0.66  0.0005867 
CA46  Mannose‐6‐phosphate  1.39  0.0147361 
CA46  Phosphocreatine  ‐0.82  0.00559057 
CA46  Phosphoserine  ‐4.27  0.00011756 
CA46  Succinate  0.62  0.0009613 
CA46  Xyulose‐5‐phosphate  ‐0.84  0.00307755 
Daudi  α‐ketoglutarate  0.95  0.00130228 
Daudi  Adenosine monophosphate  ‐0.54  0.00417053 
Daudi  Aspartic acid  ‐0.54  0.02443934 
Daudi  Cyclic adenosine monophosphate  1.36  0.03651374 
Daudi  Cis‐aconitic acid  2.29  0.00180616 
Daudi  Citrate  1.86  0.03120898 
Daudi  Creatine  ‐0.77  0.01865185 
Daudi  2' deoxyuridine‐monophosphate  ‐0.63  0.03069022 
Daudi  Fructose bisphosphate  ‐3.20  0.01142309 
Daudi  Fructose‐1‐phosphate  ‐1.13  0.00400372 
Daudi  Fumarate  0.81  0.02688549 
Daudi  Glucose‐6‐phosphate  0.59  0.00398842 
Daudi  Glutamate  ‐0.52  0.00580551 
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Cell line  Metabolites  Log2 FC  P‐value 
Daudi  Glyoxyllic acid  0.66  0.0327116 
Daudi  Guanosine  ‐2.08  0.01324557 
Daudi  Lactate  0.97  0.00066579 
Daudi  Malate  0.90  0.00330235 
Daudi  Mannose‐6‐phosphate  0.59  0.02457415 
Daudi  Orotic acid  ‐1.22  9.34E‐05 
Daudi  Phosphocreatine  ‐2.15  0.0001488 
Daudi  6‐phosphogluconate  0.93  0.04639125 
Daudi  Proline  ‐0.86  0.01248772 
Daudi  S‐5‐adenosyl‐L‐cysteine  ‐1.38  0.00186336 
Daudi  Thymidine monophosphate  ‐0.66  0.00078543 
Raji  α‐ketoglutarate  0.55  0.00422628 
Raji  Aspartic acid  ‐1.02  0.00748999 
Raji  cis Aconitic acid  2.19  1.95E‐05 
Raji  Citrate  4.21  0.00637086 
Raji  Creatine  ‐0.70  0.0101281 
Raji  2'deoxyuridine triphosphate  0.62  0.03859534 
Raji  Fructose‐6‐phosphate  1.41  0.03921023 
Raji  Glyceraldehyde‐3‐phosphate  2.00  0.00063439 
Raji  Glucose‐1‐phosphate  0.74  0.013916 
Raji  Glucose‐6‐phosphate  0.95  0.03814738 
Raji  Glutamate  ‐0.59  0.01808727 
Raji  Hydroxy‐glutaric acid  0.87  0.00015756 
Raji  Inosine monophosphate  1.75  0.00027764 
Raji  Isocitrate  2.62  0.00238449 
Raji  Lactate  0.59  0.04441402 
Raji  Malate  0.50  0.0064463 
Raji  Phosphoserine  ‐4.75  0.00588106 
Farage  α‐ketoglutarate  1.01  0.00039321 
Farage  Aspartic acid  ‐0.86  0.01500082 
Farage  Benzoic acid  ‐0.54  0.03676635 
Farage  cis‐Aconitic acid  1.43  0.00187777 
Farage  Fumarate  1.24  0.04946194 
Farage  Galactose‐1‐phosphate  0.57  0.04257316 
Farage  Glyceraldehyde‐3‐phosphate  1.96  0.02487211 
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Cell line  Metabolites  Log2 FC  P‐value 
Farage  Glucose‐6‐phosphate  1.88  0.01368217 
Farage  Glyoxyllic acid  1.63  0.03285017 
Farage  Isocitrate  2.06  0.03556178 
Farage  Malate  1.00  0.04061783 
Farage  Orotic acid  0.93  0.03812001 
OCILY18  α‐ketoglutarate  1.52  0.00075014 
OCILY18  Aspartic acid  ‐0.94  0.00100529 
OCILY18  cis‐Aconitic acid  2.38  2.59E‐06 
OCILY18  Citrate  2.76  0.00065383 
OCILY18  Cytidine‐monophosphate  ‐0.70  0.03042743 
OCILY18  2'deoxycytidine monophosphate  ‐0.92  0.01832797 
OCILY18  Fructose‐1‐phosphate  ‐1.34  0.00195119 
OCILY18  Fructose‐6‐phosphate  1.66  0.0049803 
OCILY18  Fumarate  0.60  0.0269773 
OCILY18  Glyceraldehyde‐3‐phosphate  1.43  0.00252289 
OCILY18  Glucose‐6‐phosphate  1.87  1.07E‐05 
OCILY18  Glutamate  ‐0.59  0.01381352 
OCILY18  Glyoxyllic acid  1.52  5.60E‐05 
OCILY18  Hydroxy glutaric acid  1.38  0.00202169 
OCILY18  Inosine monophosphate  1.50  7.89E‐05 
OCILY18  Isocitrate  3.40  0.00017889 
OCILY18  Lactate  0.62  0.0065629 
OCILY18  Malate  0.56  0.00150088 
OCILY18  Mannose‐6‐phosphate  1.88  0.00027798 
OCILY18  Nicotinamide adenine dinucleotide  ‐0.51  0.00945742 
OCILY18  Phosphocreatine  ‐0.91  0.00340449 
OCILY18  Phosphoserine  ‐4.61  0.00041349 
OCILY18  Pyruvate  ‐1.00  0.00038491 
OCILY18  Ribose‐5‐phosphate  ‐0.61  0.0085644 
OCILY18  Tyrosine  ‐0.65  0.00239074 
OCILY18  Uridine‐diphosphate‐glucose  ‐1.05  0.00015616 
OCILY18  Uridine monophosphate  ‐0.80  4.92E‐05 
OCILY18  Uridine  ‐1.14  0.0133522 
IMR‐32  α‐ketoglutarate  1.40  0.00020957 
IMR‐32  cis Aconitic acid  2.05  0.00029976 
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IMR‐32  Citrate  3.40  1.73E‐05 
IMR‐32  2'deoxyuridine monophosphate  ‐0.58  0.0205305 
IMR‐32  Fructose‐1‐phosphate  ‐0.85  0.00038287 
IMR‐32  Fructose‐6‐phosphate  1.32  0.00041635 
IMR‐32  Fumarate  1.85  0.00024637 
IMR‐32  Glycerate‐3‐phosphate  1.22  3.46E‐05 
IMR‐32  Glucose‐6‐phosphate  2.00  4.15E‐05 
IMR‐32  Reduced glutathione  1.43  0.04179682 
IMR‐32  Hydroxy‐glutaric acid  0.59  0.00538379 
IMR‐32  Isocitrate  2.23  0.00058534 
IMR‐32  Lactate  0.72  0.00024147 
IMR‐32  Malate  1.50  9.05E‐06 
IMR‐32  Mannose‐6‐phosphate  1.87  3.71E‐05 
IMR‐32  Phosphophenolpyruvate  1.74  0.00343812 
IMR‐32  Phosphoserine  ‐2.74  0.00018128 
IMR‐32  Pyruvate  0.94  0.00021128 
IMR‐32  Ribulose‐5‐phosphate  0.71  0.04060115 
IMR‐32  Succinate  1.02  9.15E‐05 
IMR‐32  Tryptophan  ‐0.58  0.01842709 
SH‐SY5Y  α‐ketoglutarate  1.77  6.81E‐06 
SH‐SY5Y  Adenosine monophosphate  0.55  0.02528411 
SH‐SY5Y  Aspartic acid  ‐0.97  8.03E‐05 
SH‐SY5Y  cis‐Aconitic acid  1.69  0.00024036 
SH‐SY5Y  Citrate  2.45  5.21E‐07 
SH‐SY5Y  Creatine  0.72  0.00325851 
SH‐SY5Y  Fructose‐6‐phosphate  1.25  3.48E‐05 
SH‐SY5Y  Fumarate  0.83  0.00234584 
SH‐SY5Y  Glycerate‐3‐phosphate  0.78  9.17E‐05 
SH‐SY5Y  Glyceraldehyde‐3‐phosphate  1.20  0.00074528 
SH‐SY5Y  Glycerate bisphosphate  ‐1.60  0.00264423 
SH‐SY5Y  Glucose‐6‐phosphate  1.21  0.00016866 
SH‐SY5Y  Glutamate  ‐0.56  5.79E‐05 
SH‐SY5Y  Glyoxyllic acid  1.60  0.00055379 
SH‐SY5Y  Guanosine monophosphate  1.47  0.00870991 
SH‐SY5Y  Hydroxy‐glutaric acid  1.04  0.00011156 
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SH‐SY5Y  Isocitrate  1.93  4.42E‐05 
SH‐SY5Y  Lactate  0.74  0.0001002 
SH‐SY5Y  Malate  0.62  8.75E‐05 
SH‐SY5Y  Mannose‐6‐phosphate  1.21  0.00173694 
SH‐SY5Y  Orotic acid  1.09  0.00288852 
SH‐SY5Y  Phosphocreatine  ‐0.71  0.00017369 
SH‐SY5Y  Phosphophenolpyruvate  0.55  0.00020893 
SH‐SY5Y  Phosphoserine  ‐4.14  8.81E‐05 
SH‐SY5Y  Pyruvate  0.51  0.00285791 
SH‐SY5Y  Ribulose‐5‐phosphate  0.83  0.00031764 
SH‐SY5Y  Succinate  0.51  0.01035155 
SH‐SY5Y  Uridine‐diphosphate‐glucose  ‐0.58  0.02061405 
SH‐SY5Y  Xyulose‐5‐phosphate  0.90  0.00028449 
Table 13: Full list of significantly altered metabolites following treatment with AZD3965 
in vitro.  
Metabolic changes following 2 hour treatment with AZD3965 in BL (CA46, Daudi, Raji), DLBCL 
(Farage and OCILY18) and neuroblastoma (IMR-32, SH-SY5Y) cells. Substantial alterations 
in intracellular metabolite concentrations relative to time-matched DMSO controls (+/- 0.5 Log2 
fold change), with associated P-values below 0.05 (two-tailed t-test) are indicated.
 
